Table 2.
Bivariate associations between significant proteins in the discovery subsample, and PTSD symptoms and diagnoses in the hold-out subsample.
| Discovery subsample (N = 657) | Hold-out subsample (N = 279) | ||||
|---|---|---|---|---|---|
| Significant proteins | Direction | PTSD symptoms | PTSD diagnosis | ||
| r | p value | OR (95% CI) | p value | ||
| CLM6 | Up | 0.13 | 0.031 | 1.28 (0.94–1.75) | 0.116 |
| SCARB2 | Up | 0.17 | 0.006 | 1.36 (0.99–1.86) | 0.057 |
| SIGLEC1 | Up | 0.10 | 0.091 | 1.45 (1.04–2.03) | 0.030 |
| CPM | Up | 0.10 | 0.094 | 1.50 (1.08–2.09) | 0.016 |
| RGMA | Down | −0.07 | 0.263 | 0.99 (0.73–1.36) | 0.969 |
| SMPD1 | Up | 0.10 | 0.120 | 0.96 (0.70–1.31) | 0.786 |
| CNTN5 | Down | −0.10 | 0.088 | 0.77 (0.55–1.07) | 0.114 |
| CLM1 | Up | 0.09 | 0.132 | 1.20 (0.85–1.70) | 0.307 |
| TNR | Down | –0.03 | 0.592 | 1.10 (0.80–1.50) | 0.560 |
Replicated results at nominal p < 0.050 are bolded. Associations were adjusted for age and the time lag between PTSD assessment and blood draw.